• Our Services
    • Care Navigation
    • Personalized Action Plans
    • The Cancer Commons Difference
    • Registering with Cancer Commons
    • Enhanced Services
    • Personal Tumor Boards
  • Education
    • Bladder Cancer
    • Brain Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Diffuse Midline Glioma
    • Esophageal Cancer
    • Kidney Cancer
    • Leukemia
    • Liver Cancer
    • Lung Cancer
    • Lymphoma
    • Melanoma
    • Ovarian Cancer
    • Pancreatic Cancer
    • Prostate Cancer
    • Uterine Cancer
  • About Us
    • Our Story
    • Facing Advanced Cancer
    • Meet the Team that Cares
    • Our Core Values
    • Our Partners
    • Support Our Services
    • Talk to Us
    • Financial Documents
  • Testimonials
    • All Testimonials
  • Support Us
    • Donate Now
    • Many Ways to Give
    • What Your Support Makes Possible
  • Our Services
    • Care Navigation
    • Personalized Action Plans
    • The Cancer Commons Difference
    • Registering with Cancer Commons
    • Enhanced Services
    • Personal Tumor Boards
  • Education
    • Bladder Cancer
    • Brain Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Diffuse Midline Glioma
    • Esophageal Cancer
    • Kidney Cancer
    • Leukemia
    • Liver Cancer
    • Lung Cancer
    • Lymphoma
    • Melanoma
    • Ovarian Cancer
    • Pancreatic Cancer
    • Prostate Cancer
    • Uterine Cancer
  • About Us
    • Our Story
    • Facing Advanced Cancer
    • Meet the Team that Cares
    • Our Core Values
    • Our Partners
    • Support Our Services
    • Talk to Us
    • Financial Documents
  • Testimonials
    • All Testimonials
  • Support Us
    • Donate Now
    • Many Ways to Give
    • What Your Support Makes Possible
 

Molecular Testing Options

Molecular tests help match patients to the personalized treatments that are most likely to work for them. Keep up with new developments in genetic tests, blood tests, liquid biopsies, tumor mutations, other biomarkers, precision medicine, next-generation sequencing, and more.

  • October 30, 2015  

    To Type or to Print? Oncotype DX and Mamma/BluePrint Tests for Breast Cancer

    Emma Shtivelman, PhD

    Women diagnosed with localized breast cancer face difficult decisions with their doctors. What kind of neoadjuvant (before surgery) treatment to choose? Should chemotherapy follow surgery? Based on the subtype of breast cancer, should specific chemotherapy drugs be used?

  • September 9, 2015  

    To PD-L1 or Not to PD-L1: That Is the Question

    Emma Shtivelman, PhD

    These days, it seems that I write mostly about immune checkpoint blockade drugs, or some other new immunotherapy treatment for cancer. This post is no different—it covers PD-L1, a protein that is at the center of clinical decisions for selecting patients who are likely to benefit from treatment with an anti-PD-1 or anti-PD-L1 drug.

  • August 13, 2015  

    What Determines Whether a Melanoma Patient Will Respond to Checkpoint Blockade Drugs?

    Emma Shtivelman, PhD

    Of all cancer types, melanoma is the most investigated in terms of its potential to be treated through immune system-based approaches. More immunotherapy drugs are approved for melanoma than for any other type of cancer, and more are in development. Recent additions to the immunotherapy arsenal are the ‘anti-PD-1’ immune checkpoint blockade drugs pembrolizumab (Keytruda) and nivolumab (Opdivo).

    • «
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6

I’d already been leaning heavily towards a decision, and Emma helped me achieve the final decision…But Emma’s more than a scientist. She is a caring person.

Ellen
Breast cancer patient



It has been extremely gratifying to see how Cancer Commons has brought clarity and greater access to this expertise through its convening and curation.

Keith Flaherty, MD
Cancer Commons Advisor

Cancer Commons, a patient-centric nonprofit, features compassionate experts who build relationships with advanced cancer patients and caregivers to create personalized action plans. Our nurse navigators, PhD scientists, and national experts consult the latest, most-promising research to identify, explain, and help patients access their best-possible diagnostic and treatment options—so everyone feels confident they’ve left no stone unturned.

Don’t miss Cancer Commons Connects
Exclusive monthly insights and stories—from and for our community

Working.

Dealing with Cancer? Let Us Help

Our Services

  • Care Navigation
  • Personalized Action Plans
  • Registering with Cancer Commons
  • Enhanced Services
  • Personal Tumor Boards
  • Frequently Asked Questions (FAQ)

Perspectives

  • Latest Research
  • Treatment Options
  • Molecular Testing
  • Navigating Treatment
  • Living with Cancer
  • Patient Stories
  • Curious Dr. George
  • The Big Picture
  • Peer-Reviewed Publications

Organization

  • Our Story
  • Our Team
  • Our Core Values
  • Contact Us
  • Board of Directors
  • Partners
  • Expert Physician Advisors

About Us

  • News and Events
  • Contact Us
  • Financial Documents

Support & Giving

  • Contribute Now
  • Many Ways to Give
  • What Your Support Makes Possible
  • Testimonials


Donate

Cancer Commons
650 Castro Street, Suite 120-522
Mountain View, CA 94041, USA
650-289-4044

Patients Hotline

877-971-1200

  • Privacy Policy

© 2023 Cancer Commons.